Developer docs
API playgroundTry for free, no card

Search company profiles

Caldera Therapeutics

Full company profile

uuid00kddva

Namestring
Caldera Therapeutics
Legal namestring
Caldera Therapeutics, Inc.
Websiteurl
calderatx.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Caldera Therapeutics is a clinical-stage biotechnology company founded in 2025 and officially launched in January 2026, headquartered at 300 Technology Square in Cambridge, Massachusetts. The company is developing CLD-423, a first-in-class bispecific antibody that simultaneously targets the IL-23p19 and TL1A pathways — two clinically validated mechanisms in autoimmune disease. Caldera acquired the program by in-licensing exclusive global development and commercialization rights to CLD-423 from Qyuns Therapeutics Co., Ltd., and the asset is currently in a Phase 1 healthy volunteer trial.

The underlying technology is a rationally engineered bispecific antibody designed to deliver a best-in-disease profile across efficacy, safety, pharmacokinetics, and developability. By combining IL-23p19 and TL1A inhibition in a single molecule, Caldera is positioning the program to address what the company characterizes as an efficacy ceiling in single-target IBD therapies, with stated optionality to expand into other immunologic and inflammatory diseases. Caldera has assembled a leadership team anchored by individuals with prior exits and large-pharma experience, including CEO Praveen Tipirneni, who previously led Morphic Therapeutic through its $3.2 billion acquisition by Eli Lilly.

Caldera is pre-revenue and operates as a venture-backed development-stage biotech. It funds operations through institutional venture capital — having raised $112.5 million across a $75 million Series A (Atlas Venture, LAV, venBio) and a $37.5 million Series A-1 (Omega Funds lead, with Wellington Management and Janus Henderson Investors). The company serves an end-patient population of IBD patients (Crohn's disease and ulcerative colitis), and upon regulatory approval will distribute CLD-423 through standard pharmaceutical channels — specialty pharmacy networks and hospital purchasing systems — with no pricing or commercial details disclosed today.

Short descriptiontext

Caldera Therapeutics is a clinical-stage biotechnology company developing CLD-423, a first-in-class bispecific antibody targeting IL-23p19 and TL1A pathways for inflammatory bowel disease, with a Phase 1 healthy volunteer trial currently ongoing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibodies, inflammatory bowel disease, immunology therapeutics, biologics development, clinical stage biotechnology
Industry2 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Bispecific Antibody Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Pre-revenue clinical stage biotechnology company. The company will generate revenue through the eventual commercialization of its bispecific antibody therapeutic CLD-423 upon regulatory approval. Revenue model will follow traditional pharmaceutical sales channels for prescription biologics.

citybiz.co
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Caldera Therapeutics is a clinical-stage biotechnology company developing CLD-423, a first-in-class bispecific antibody that simultaneously targets the IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. The molecule is rationally designed to achieve a best-in-disease profile with optimized efficacy, safety, pharmacokinetics, and developability. The company in-licensed global development and commercialization rights to CLD-423 from Qyuns Therapeutics Co., Ltd.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 1 healthy volunteer trial initiated with first subjects dosed
Product overview1 text field

Caldera Therapeutics is a clinical-stage biotechnology company developing a single product, CLD-423, which is a first-in-class bispecific antibody. CLD-423 is the company's sole pipeline asset, targeting the IL-23p19 and TL1A pathways for treatment of inflammatory bowel disease and other immunologic/inflammatory diseases. The company launched in January 2026 with $112.5 million in funding and a Phase 1 healthy volunteer trial is ongoing for CLD-423.

Product and service1 record
1CLD-423
CategoryBispecific Antibody Therapeutics
Description

CLD-423 is a first-in-class bispecific antibody that targets both the IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. It is rationally designed to achieve a best-in-disease profile with optimized efficacy, safety, pharmacokinetics, and developability, and is currently in a Phase 1 healthy volunteer trial.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Caldera Therapeutics in-licensed exclusive global development and commercialization rights to CLD-423 from Qyuns Therapeutics Co., Ltd. This licensing agreement provides Caldera with the foundational intellectual property for its lead bispecific antibody program targeting IL-23p19 and TL1A pathways.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Bristol Myers Squibb
TypeBroad incumbent
Description

Markets Zeposia (ozanimod, S1P modulator) for ulcerative colitis and runs active Phase 2–3 gastroenterology programs. Caldera's SVP Clinical Development (Danny Oh) previously led IBD trials at BMS, indicating a competitor with operational overlap.

TypeBroad incumbent
Description

Houses multiple Vant subsidiaries developing IBD and immunology therapies (including TL1A-focused programs). A broader, well-capitalized player pursuing adjacent mechanisms in the same indication space.

TypeDirect peer
Description

Clinical-stage biotech developing novel oral therapeutics for IBD (e.g., omilancor, NX-13); acquired by AbbVie in 2024. Comparable as a small-cap IBD biotech with a single mechanistic thesis acquired by a major player.

TypeBroad incumbent
Description

Markets Humira and Skyrizi (risankizumab, anti-IL-23) — the leading IL-23p19 inhibitor approved for Crohn's disease and ulcerative colitis. Sets the efficacy/safety bar CLD-423 must exceed to differentiate in IBD.

TypeBroad incumbent
Description

Markets Stelara (ustekinumab) and Tremfya (guselkumab) for IBD. A leading immunology incumbent whose IL-23 pathway franchise overlaps with one of CLD-423's targets.

TypeBroad incumbent
Description

Acquired Morphic Holding in 2024 for its IBD integrin program; large pharma with growing immunology franchise. Relevant as a likely strategic acquirer profile for Caldera.

7Morphic Holding
TypeDirect peer
Description

Developed oral integrin inhibitors for IBD; acquired by Eli Lilly in 2024 for $3.2B. Direct comparator for an IBD-focused clinical-stage biotech with a single-asset profile and is the prior company of Caldera's CEO and several executives.

TypeBroad incumbent
Description

Markets Entyvio (vedolizumab), the leading integrin antagonist for IBD; Caldera's CPO (Colm White) previously led Entyvio's global launch at Takeda. A major incumbent in the same therapeutic class.

9Prometheus Biosciences
TypeDirect peer
Description

Developed PRA023, an anti-TL1A monoclonal antibody for IBD and other immunologic diseases; acquired by Merck in 2023 for ~$10.8B. Highly comparable as a TL1A-pathway IBD biologic at similar clinical-stage risk profile.

TypeEmerging player
Description

Clinical-stage biotech developing oral immunology therapies for IBD, including ulcerative colitis. Caldera's SVP of Clinical Development Operations (Pam Wedel) most recently led early-phase IBD work at Sorriso, signaling direct operational comparability.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Caldera Therapeutics

Bispecific Antibody Therapeuticscalderatx.com

Caldera Therapeutics is a clinical-stage biotechnology company developing CLD-423, a first-in-class bispecific antibody targeting IL-23p19 and TL1A pathways for inflammatory bowel disease, with a Phase 1 healthy volunteer trial currently ongoing.

What Caldera Therapeutics does

Caldera Therapeutics is a clinical-stage biotechnology company founded in 2025 and officially launched in January 2026, headquartered at 300 Technology Square in Cambridge, Massachusetts. The company is developing CLD-423, a first-in-class bispecific antibody that simultaneously targets the IL-23p19 and TL1A pathways — two clinically validated mechanisms in autoimmune disease. Caldera acquired the program by in-licensing exclusive global development and commercialization rights to CLD-423 from Qyuns Therapeutics Co., Ltd., and the asset is currently in a Phase 1 healthy volunteer trial.

The underlying technology is a rationally engineered bispecific antibody designed to deliver a best-in-disease profile across efficacy, safety, pharmacokinetics, and developability. By combining IL-23p19 and TL1A inhibition in a single molecule, Caldera is positioning the program to address what the company characterizes as an efficacy ceiling in single-target IBD therapies, with stated optionality to expand into other immunologic and inflammatory diseases. Caldera has assembled a leadership team anchored by individuals with prior exits and large-pharma experience, including CEO Praveen Tipirneni, who previously led Morphic Therapeutic through its $3.2 billion acquisition by Eli Lilly.

Caldera is pre-revenue and operates as a venture-backed development-stage biotech. It funds operations through institutional venture capital — having raised $112.5 million across a $75 million Series A (Atlas Venture, LAV, venBio) and a $37.5 million Series A-1 (Omega Funds lead, with Wellington Management and Janus Henderson Investors). The company serves an end-patient population of IBD patients (Crohn's disease and ulcerative colitis), and upon regulatory approval will distribute CLD-423 through standard pharmaceutical channels — specialty pharmacy networks and hospital purchasing systems — with no pricing or commercial details disclosed today.

Caldera Therapeutics firmographics

Firmographics
Name
Caldera Therapeutics
Legal name
Caldera Therapeutics, Inc.
Website
https://calderatx.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
Caldera Therapeutics is a clinical-stage biotechnology company developing CLD-423, a first-in-class bispecific antibody targeting IL-23p19 and TL1A pathways for inflammatory bowel disease, with a Phase 1 healthy volunteer trial currently ongoing.
Ownership category
akta.pro rank

Caldera Therapeutics industry classification

Industry
Product category
Bispecific Antibody Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Bispecific antibodies
  • Inflammatory bowel disease
  • Immunology therapeutics
  • Biologics development
  • Clinical stage biotechnology

Where Caldera Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Caldera Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical Drug Sales: Pre-revenue clinical stage biotechnology company. The company will generate revenue through the eventual commercialization of its bispecific antibody therapeutic CLD-423 upon regulatory approval. Revenue model will follow traditional pharmaceutical sales channels for prescription biologics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Caldera Therapeutics product offering

Product offering

Core offering

Caldera Therapeutics is a clinical-stage biotechnology company developing CLD-423, a first-in-class bispecific antibody that simultaneously targets the IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. The molecule is rationally designed to achieve a best-in-disease profile with optimized efficacy, safety, pharmacokinetics, and developability. The company in-licensed global development and commercialization rights to CLD-423 from Qyuns Therapeutics Co., Ltd.

Product overview

Caldera Therapeutics is a clinical-stage biotechnology company developing a single product, CLD-423, which is a first-in-class bispecific antibody. CLD-423 is the company's sole pipeline asset, targeting the IL-23p19 and TL1A pathways for treatment of inflammatory bowel disease and other immunologic/inflammatory diseases. The company launched in January 2026 with $112.5 million in funding and a Phase 1 healthy volunteer trial is ongoing for CLD-423.

Differentiator

Problem solved

Functional benefit

Products and services

  • CLD-423 CLD-423 is a first-in-class bispecific antibody that targets both the IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. It is rationally designed to achieve a best-in-disease profile with optimized efficacy, safety, pharmacokinetics, and developability, and is currently in a Phase 1 healthy volunteer trial.

Quantifiable outcome

  • Phase 1 healthy volunteer trial initiated with first subjects dosed

Companies that use Caldera Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Caldera Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Caldera Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Qyuns Therapeutics Co., Ltd.coreStrategic or Co-development Partner · 1 January 2025Caldera Therapeutics in-licensed exclusive global development and commercialization rights to CLD-423 from Qyuns Therapeutics Co., Ltd. This licensing agreement provides Caldera with the foundational intellectual property for its lead bispecific antibody program targeting IL-23p19 and TL1A pathways.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Caldera Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Bristol Myers Squibb: Markets Zeposia (ozanimod, S1P modulator) for ulcerative colitis and runs active Phase 2–3 gastroenterology programs. Caldera's SVP Clinical Development (Danny Oh) previously led IBD trials at BMS, indicating a competitor with operational overlap.
  • Roivant Sciences: Houses multiple Vant subsidiaries developing IBD and immunology therapies (including TL1A-focused programs). A broader, well-capitalized player pursuing adjacent mechanisms in the same indication space.
  • AbbVie: Markets Humira and Skyrizi (risankizumab, anti-IL-23) — the leading IL-23p19 inhibitor approved for Crohn's disease and ulcerative colitis. Sets the efficacy/safety bar CLD-423 must exceed to differentiate in IBD.
  • Johnson & Johnson: Markets Stelara (ustekinumab) and Tremfya (guselkumab) for IBD. A leading immunology incumbent whose IL-23 pathway franchise overlaps with one of CLD-423's targets.
  • Eli Lilly: Acquired Morphic Holding in 2024 for its IBD integrin program; large pharma with growing immunology franchise. Relevant as a likely strategic acquirer profile for Caldera.
  • Takeda Pharmaceutical: Markets Entyvio (vedolizumab), the leading integrin antagonist for IBD; Caldera's CPO (Colm White) previously led Entyvio's global launch at Takeda. A major incumbent in the same therapeutic class.

Direct peers

  • Landos Biopharma: Clinical-stage biotech developing novel oral therapeutics for IBD (e.g., omilancor, NX-13); acquired by AbbVie in 2024. Comparable as a small-cap IBD biotech with a single mechanistic thesis acquired by a major player.
  • Morphic Holding: Developed oral integrin inhibitors for IBD; acquired by Eli Lilly in 2024 for $3.2B. Direct comparator for an IBD-focused clinical-stage biotech with a single-asset profile and is the prior company of Caldera's CEO and several executives.
  • Prometheus Biosciences: Developed PRA023, an anti-TL1A monoclonal antibody for IBD and other immunologic diseases; acquired by Merck in 2023 for ~$10.8B. Highly comparable as a TL1A-pathway IBD biologic at similar clinical-stage risk profile.

Emerging players

  • Sorriso Pharmaceuticals: Clinical-stage biotech developing oral immunology therapies for IBD, including ulcerative colitis. Caldera's SVP of Clinical Development Operations (Pam Wedel) most recently led early-phase IBD work at Sorriso, signaling direct operational comparability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Caldera Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Caldera Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Caldera Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Caldera Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Caldera Therapeutics

What does Caldera Therapeutics do?

Caldera Therapeutics is a clinical-stage biotechnology company developing CLD-423, a first-in-class bispecific antibody that simultaneously targets the IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. The molecule is rationally designed to achieve a best-in-disease profile with optimized efficacy, safety, pharmacokinetics, and developability. The company in-licensed global development and commercialization rights to CLD-423 from Qyuns Therapeutics Co., Ltd.

Is Caldera Therapeutics a public or private company?

Caldera Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Caldera Therapeutics founded?

Caldera Therapeutics was founded in 2025. It employs 11 to 50 people.

Where is Caldera Therapeutics based?

Caldera Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Caldera Therapeutics make money?

One revenue line is on record: pharmaceutical Drug Sales.

Who are Caldera Therapeutics's main competitors?

Broad incumbents on record are Bristol Myers Squibb, Roivant Sciences, AbbVie, Johnson & Johnson, Eli Lilly and Takeda Pharmaceutical. Direct peers are Landos Biopharma, Morphic Holding and Prometheus Biosciences. Sorriso Pharmaceuticals is listed as an emerging player.

Does Caldera Therapeutics have an API?

No public API is recorded for Caldera Therapeutics.

What industry is Caldera Therapeutics in?

Caldera Therapeutics's product category is Bispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型Qyuns Hands Caldera Preclinical TL1A×IL-17 BsAb for Up to USD 780mnQyuns Therapeutics granted Caldera Therapeutics worldwide rights to a preclinical TL1A×IL-17 bispecific antibody, receiving a USD 30 million upfront payment and eligibility for up to USD 750 million in milestones plus tiered royalties. The deal gives Caldera full global control of development and commercialization.Morningstar$HAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of the Merger - BWMN, SUNS, DV and SYBXMonteverde & Associates PC announced investigations into four mergers: Bowman Consulting's sale to Bernhard Capital Partners, Blue Sunrise Realty's merger with Southern Realty, DoubleVerify's sale to Nielsen, and Synlogic's merger with Caldera. Deal terms include $43 per Bowman share, $13.60 per DoubleVerify share, and Sunrise shareholders expected to own 62% of the combined company.Business Wire BlogSYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its ShareholdersHalper Sadeh LLC is investigating the merger of Synlogic and Caldera Therapeutics, alleging the deal may not provide fair value to Synlogic shareholders. The firm claims shareholders would own about 2.3% of the combined company and seeks increased consideration or additional disclosures.YahooSynlogic and Caldera Therapeutics Announce Merger and $278 Million Private PlacementSynlogic announced a definitive merger agreement with clinical-stage biotechnology company Caldera Therapeutics in an all-stock transaction that will create a new publicly traded company focused on Caldera's inflammatory bowel disease pipeline. The concurrent upsized private placement is expected to raise approximately $278 million from healthcare-focused institutional investors to fund development of CLD-423 through Phase 2 clinical trials, with operations projected to be funded into 2029. The combined company will operate as Caldera Therapeutics and intends to list on Nasdaq under the ticker symbol CALD.YahooCaldera, Vidya add to recent flurry of biotech mergersCaldera Therapeutics and Vidya Therapeutics announced separate merger deals on Wednesday as part of a recent wave of biotech consolidation around China-licensed assets. Caldera will merge with struggling Synlogic and raise $278 million in private financing to advance CLD-423, a drug licensed from China's Qyuns Therapeutics targeting inflammation pathways, with Phase 1 data expected by end of 2026. Separately, Processa Pharmaceuticals is acquiring Vidya along with $200 million in private funding to develop VT-7208, a BTK inhibitor in Phase 2 testing for food allergies, chronic spontaneous urticaria, and relapsing multiple sclerosis, with both deals expected to fund operations into 2029.BioPharma DiveCaldera, Vidya add to recent flurry of biotech mergersCaldera Therapeutics and Vidya Therapeutics separately announced merger and acquisition deals on Wednesday, both accompanied by large private financings to advance drug candidates into later-stage development. Caldera will merge with Synlogic and raise $278 million to fund CLD-423, a drug licensed from China's Qyuns Therapeutics targeting inflammation, while Processa Pharmaceuticals is acquiring Vidya with $200 million to support VT-7208, a BTK inhibitor advancing into Phase 2 for food allergies and neurological conditions. Both deals are expected to fund company operations into 2029 and reflect a broader trend of biotech mergers built around China-licensed assets.Business Wire BlogSynlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private PlacementSynlogic, Inc. and privately held Caldera Therapeutics, Inc. have entered into a definitive merger agreement to combine in an all-stock transaction, with the combined company to operate under the Caldera Therapeutics name and list on Nasdaq under the ticker symbol "CALD." Caldera has simultaneously secured a $278 million private placement from healthcare institutional investors, including Bain Capital Life Sciences, TCGX, Atlas Venture, and others, which is expected to fund Phase 2 clinical development of its lead asset CLD-423 in ulcerative colitis and Crohn's disease through 2029. The transaction, approved by both boards and expected to close by early 2027, will result in pre-merger Caldera stockholders owning approximately 62.8% of the combined company.Stock TitanSynlogic Agrees to Caldera Merger, $278M PlacementSynlogic, Inc. and Caldera Therapeutics, Inc. have entered into a definitive merger agreement to combine in an all-stock transaction, with the resulting company to operate as Caldera Therapeutics, Inc. and list on Nasdaq under the ticker symbol CALD. Caldera has secured a concurrent upsized private placement of approximately $278 million from a syndicate of healthcare institutional investors, including Bain Capital Life Sciences, TCGX, Atlas Venture, and others, to fund Phase 2 clinical trials of CLD-423 in ulcerative colitis and Crohn's disease through 2029. CLD-423 is a potential first-in-class bispecific antibody targeting TL1A and IL-23p19 pathways for inflammatory bowel disease and other immune-mediated diseases, currently completing Phase 1 trials in Australia.FinancialContent Business PageSynlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private PlacementSynlogic, Inc. and Caldera Therapeutics, Inc. have entered into a definitive all-stock merger agreement, combining to operate under the name Caldera Therapeutics, Inc. with plans to list on Nasdaq under the ticker symbol "CALD." The companies have secured a concurrent upsized private placement of approximately $278 million from a syndicate of healthcare institutional investors, which is expected to fund the combined company's operations through Phase 2 clinical trials in ulcerative colitis and Crohn's disease into 2029. The transaction, expected to close by early 2027 pending stockholder and regulatory approvals, will result in pre-merger Caldera stockholders owning approximately 62.8% of the combined company.BioSpaceSynlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private PlacementSynlogic and Caldera Therapeutics announced a merger agreement to combine in an all-stock transaction, with the combined company operating as Caldera Therapeutics. Caldera secured a concurrent private placement of approximately $278 million to fund Phase 2 clinical trials, with cash runway projected into 2029. The deal is expected to close by early 2027.